Maxime Van Houdt

Dr. Maxime Van Houdt

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


8 January 2026 in ESMO Open
Verified
Journal Article
Open access
MHMaxime Van Houdt
Maxime Van Houdt
CKCindy Kenis
Cindy Kenis
LNL. De Nys
L. De Nys
SHS. Hatse
S. Hatse
PNP. Neven
P. Neven
HWhans wildiers
hans wildiers
Cyclin-dependent kinase 4/6 inhibitors with endocrine therapy are standard first-line therapy for patients with hormone receptor-positive metastatic breast cancer. Older patients, especially the frailer subpopulation, are underrepresented in clinical trials, limiting data on treatment and safety outcomes in this population. The RibOB study was an open-label, single-arm phase IV prospective trial evaluating first-line ribociclib 600 mg 3 weeks out of 4 with letrozole in women ≥70 years with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Primary endpoint was progression-free survival (PFS). Secondary endpoints were safety, functional evolution and quality of life (QoL), and outcomes in relation to clinical frailty assessed by G8. Seventy patients were enrolled: median age 76 years, with 30% ≥80 years. Forty-five out of 70 patients had a G8 score of ≤14 (frail) at baseline. With a median follow-up of 30.5 months, the median PFS was 36 months (95% confidence interval 24 months-not estimable). Median overall survival rate was not reached and breast cancer-specific survival rate at 24 and 36 months was 82% and 75%, respectively. Median time to treatment failure was 14.6 months. There were no significant differences in efficacy between fit and frail patients. Forty-seven out of 70 patients (67%) had grade 3 or higher adverse events, most commonly neutropenia (47%). Liver toxicity grade 3 or higher occurred in 2/70 (3%), and grade 3 or higher QT prolongation in 3/70 (4%). Thirty out of 70 patients (43%) discontinued ribociclib before progression and 57% required dose reductions to 400 mg, and 23% to 200 mg. Only 14 patients (20%) continued with the full 600-mg dose until end of study, disease progression, or death. No significant change in mean QoL was observed over time. Ribociclib in combination with letrozole showed clear antitumor efficacy and safe treatment option in older patients with advanced breast cancer regardless of frailty. Frequent dose reductions and early discontinuation suggest the need for more research to optimize dosing in older patients.

11 November 2024 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
MHMaxime Van Houdt
Maxime Van Houdt
TFTom Fidlers
Tom Fidlers
PNPatrick Neven
Patrick Neven
SHSileny Han
Sileny Han
Intravascular papillary endothelial hyperplasia, or Masson’s tumour, is a benign lesion of the subcutaneous tissue and skin, characterised by a reactive proliferation of endothelial cells within a vessel. Although this pathology can occur at various sites, it is generally rare. Differential diagnosis with other benign lesions or malignancies can be challenging, and since its circumscribed nature is impossible to recognise with a biopsy, excision is frequently required. We present the case of a female patient with a history of bilateral breast cancer, treated with surgery, chemotherapy and radiotherapy, who developed a slowly growing, large bulging mass in the right axilla. Biopsies were benign, and the positron emission tomography–CT showed no hypermetabolism of the mass. However, due to the debilitating bleeding from the fragile mass and uncertainty about its biological behaviour, excision was performed. Pathological examination revealed an intravascular lesion with a central thrombus, characteristic of intravascular papillary endothelial hyperplasia.

3 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
PHPeh Joo Ho
Peh Joo Ho
KLKim Yan Christine Loo
Kim Yan Christine Loo
RLRyan Jak Yang Lim
Ryan Jak Yang Lim
MGMeng Huang Goh
Meng Huang Goh
MAMustapha Abubakar
Mustapha Abubakar
SISGBCC Investigators
SGBCC Investigators
Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (<50 years) women (OR = 2.51, AUC = 0.622) than in women ≥ 50 years (OR = 2.06, AUC = 0.653) of European ancestry. PRS performance in Asians was lower (OR range = 1.62–1.64, AUC = 0.551–0.600). Gail performance was modest across groups and poor in younger Asian women (OR = 0.94–0.99, AUC = 0.523–0.533). Age interactions were observed for both PRS (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.

14 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ZMZoe Molinari
Zoe Molinari
NDNancy Van Damme
Nancy Van Damme
JVJulie Verbeeck
Julie Verbeeck
ALAnnouschka Laenen
Annouschka Laenen
SHSileny N. Han
Sileny N. Han
Patrick NevenPatrick Neven
Patrick Neven
Tamoxifen increases the risk of endometrial cancer (ECa) when treating breast cancer (BC)in postmenopausal women, but the impact in premenopausal women is not well established. A retrospective study in South-Korea suggested that premenopausal BC patients were 3.77 times more likely to develop ECa when treated with tamoxifen. We aimed to validate these results in a large-scale nationwide study in Belgium.We conducted a retrospective cohort study in women, aged 18–53, diagnosed with non-metastatic BC in Belgium between 2008 and 2020. Patients treated with tamoxifen were compared to those not treated with tamoxifen by baseline characteristics and diagnosis of ECa. The primary endpoint was time to ECa diagnosis. A Cox proportional hazards model assessed the primary endpoint, with treatment group as the main variable and patient/tumor characteristics as covariates.We included 23 289 patients (60%; median age 47 years) in the tamoxifen group and 15 568 patients (40%; median age 47 years) in the non-tamoxifen group. Tamoxifen users were more likely to have low-grade and lobular tumors, and less likely to receive (neo-)adjuvant or targeted (chemo)therapy. 96 ECa events occurred in the tamoxifen group (0.41%) and 27 in the non-tamoxifen group (0.17%). This translated to 0.51% and 0.22% of survivors, respectively which was a statistically significant difference (HR 2.05, CI: 1.34-3.15). After adjusting for potential confounders—diabetes, cardiovascular profile, tumor grade, pT, pN, chemotherapy, and targeted therapy—the risk remained significantly elevated in the tamoxifen group (adjusted HR 1.93, CI: 1.14-3.28; p = 0.0141).